ArticleProteome science2016
The association of plasma cystatin C proteoforms with diabetic chronic kidney disease.
Article in Proteome science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA.Arteriosclerosis, thrombosis, and vascular biology · 2023Observational
- A nomogram for predicting the 4-year risk of chronic kidney disease among Chinese elderly adults.International urology and nephrology · 2023Review
- Cystatin C proteoforms in chronic kidney disease.PloS one · 2023Article
- The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms.Nucleic acids research · 2022Article
- Uncovering Molecular Heterogeneity in the Kidney With Spatially Targeted Mass Spectrometry.Frontiers in physiology · 2022Review
- Review
- Roles of Hydrogen Sulfide Donors in Common Kidney Diseases.Frontiers in pharmacology · 2020Review
- Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis.Archives of medical science : AMS · 2020Review
- Value of elastography point quantification in improving the diagnostic accuracy of early diabetic kidney disease.World journal of clinical cases · 2019Article
- Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.Proteomes · 2017Review
- Article
- Association of Cystatin C Proteoforms with Estimated Glomerular Filtration Rate.Clinical mass spectrometry (Del Mar, Calif.) · 2016Article
- Biomarkers for predicting outcomes in chronic kidney disease.Current opinion in nephrology and hypertension · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD).
resultsUsing mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations.
conclusionOur findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.